Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT.
Mark G RabbatSuvasini LakshmananMina M BenjaminGheorghe DorosApril KinningerMatthew J BudoffDeepak L BhattPublished in: European heart journal. Cardiovascular Imaging (2023)
Icosapent ethyl demonstrated significant benefits in coronary physiology compared with placebo. This early and sustained improvement in FFRCT at 9- and 18-month follow-up provides mechanistic insight into the clinical benefit observed in the REDUCE-IT trial. Furthermore, this is the first assessment of FFRCT to determine drug effect.
Keyphrases
- coronary artery
- coronary artery disease
- phase iii
- ionic liquid
- study protocol
- clinical trial
- aortic stenosis
- phase ii
- emergency department
- open label
- double blind
- magnetic resonance imaging
- heart failure
- randomized controlled trial
- left ventricular
- ejection fraction
- computed tomography
- adverse drug
- image quality
- contrast enhanced